589 related articles for article (PubMed ID: 31681327)
1. T Regulatory Cells and Priming the Suppressive Tumor Microenvironment.
Paluskievicz CM; Cao X; Abdi R; Zheng P; Liu Y; Bromberg JS
Front Immunol; 2019; 10():2453. PubMed ID: 31681327
[TBL] [Abstract][Full Text] [Related]
2. Tumor microenvironment dictates regulatory T cell phenotype: Upregulated immune checkpoints reinforce suppressive function.
Kim HR; Park HJ; Son J; Lee JG; Chung KY; Cho NH; Shim HS; Park S; Kim G; In Yoon H; Kim HG; Jung YW; Cho BC; Park SY; Rha SY; Ha SJ
J Immunother Cancer; 2019 Dec; 7(1):339. PubMed ID: 31801611
[TBL] [Abstract][Full Text] [Related]
3. Remodeling of the tumor microenvironment via disrupting Blimp1
Dixon ML; Luo L; Ghosh S; Grimes JM; Leavenworth JD; Leavenworth JW
Mol Cancer; 2021 Nov; 20(1):150. PubMed ID: 34798898
[TBL] [Abstract][Full Text] [Related]
4. Immunometabolic Checkpoints of Treg Dynamics: Adaptation to Microenvironmental Opportunities and Challenges.
Pacella I; Piconese S
Front Immunol; 2019; 10():1889. PubMed ID: 31507585
[TBL] [Abstract][Full Text] [Related]
5. Intratumoral regulatory T cells: markers, subsets and their impact on anti-tumor immunity.
Yano H; Andrews LP; Workman CJ; Vignali DAA
Immunology; 2019 Jul; 157(3):232-247. PubMed ID: 31087644
[TBL] [Abstract][Full Text] [Related]
6. Preferential accumulation of regulatory T cells with highly immunosuppressive characteristics in breast tumor microenvironment.
Syed Khaja AS; Toor SM; El Salhat H; Faour I; Ul Haq N; Ali BR; Elkord E
Oncotarget; 2017 May; 8(20):33159-33171. PubMed ID: 28388539
[TBL] [Abstract][Full Text] [Related]
7. Metabolic profiles of regulatory T cells in the tumour microenvironment.
Rao D; Verburg F; Renner K; Peeper DS; Lacroix R; Blank CU
Cancer Immunol Immunother; 2021 Sep; 70(9):2417-2427. PubMed ID: 33576875
[TBL] [Abstract][Full Text] [Related]
8. Unlocking the Complexities of Tumor-Associated Regulatory T Cells.
Chao JL; Savage PA
J Immunol; 2018 Jan; 200(2):415-421. PubMed ID: 29311383
[TBL] [Abstract][Full Text] [Related]
9. Recent advances in the role of Th17/Treg cells in tumor immunity and tumor therapy.
Qianmei Y; Zehong S; Guang W; Hui L; Lian G
Immunol Res; 2021 Oct; 69(5):398-414. PubMed ID: 34302619
[TBL] [Abstract][Full Text] [Related]
10. Targeting regulatory T cells in tumors.
Liu C; Workman CJ; Vignali DA
FEBS J; 2016 Jul; 283(14):2731-48. PubMed ID: 26787424
[TBL] [Abstract][Full Text] [Related]
11. CD36-mediated metabolic adaptation supports regulatory T cell survival and function in tumors.
Wang H; Franco F; Tsui YC; Xie X; Trefny MP; Zappasodi R; Mohmood SR; Fernández-García J; Tsai CH; Schulze I; Picard F; Meylan E; Silverstein R; Goldberg I; Fendt SM; Wolchok JD; Merghoub T; Jandus C; Zippelius A; Ho PC
Nat Immunol; 2020 Mar; 21(3):298-308. PubMed ID: 32066953
[TBL] [Abstract][Full Text] [Related]
12. Stereotactic Radiotherapy Increases Functionally Suppressive Regulatory T Cells in the Tumor Microenvironment.
Muroyama Y; Nirschl TR; Kochel CM; Lopez-Bujanda Z; Theodros D; Mao W; Carrera-Haro MA; Ghasemzadeh A; Marciscano AE; Velarde E; Tam AJ; Thoburn CJ; Uddin M; Meeker AK; Anders RA; Pardoll DM; Drake CG
Cancer Immunol Res; 2017 Nov; 5(11):992-1004. PubMed ID: 28970196
[TBL] [Abstract][Full Text] [Related]
13. Epigenetical Targeting of the FOXP3 Gene by S-Adenosylmethionine Diminishes the Suppressive Capacity of Regulatory T Cells Ex Vivo and Alters the Expression Profiles.
Sahin E; Sahin M
J Immunother; 2019 Jan; 42(1):11-22. PubMed ID: 30407230
[TBL] [Abstract][Full Text] [Related]
14. Highly immunosuppressive HLADR
Yang H; Ye S; Goswami S; Li T; Wu J; Cao C; Ma J; Lu B; Pei X; Chen Y; Yu J; Xu H; Qiu L; Afridi S; Xiang L; Zhang X
Int J Cancer; 2020 Apr; 146(7):1993-2006. PubMed ID: 31709528
[TBL] [Abstract][Full Text] [Related]
15. Regulatory T cells in breast cancer as a potent anti-cancer therapeutic target.
Hashemi V; Maleki LA; Esmaily M; Masjedi A; Ghalamfarsa G; Namdar A; Yousefi M; Yousefi B; Jadidi-Niaragh F
Int Immunopharmacol; 2020 Jan; 78():106087. PubMed ID: 31841758
[TBL] [Abstract][Full Text] [Related]
16. Colorectal Cancer-Infiltrating Regulatory T Cells: Functional Heterogeneity, Metabolic Adaptation, and Therapeutic Targeting.
Aristin Revilla S; Kranenburg O; Coffer PJ
Front Immunol; 2022; 13():903564. PubMed ID: 35874729
[TBL] [Abstract][Full Text] [Related]
17. Treg Fragility: A Prerequisite for Effective Antitumor Immunity?
Overacre-Delgoffe AE; Vignali DAA
Cancer Immunol Res; 2018 Aug; 6(8):882-887. PubMed ID: 30068755
[TBL] [Abstract][Full Text] [Related]
18. Novel anti-GARP antibody DS-1055a augments anti-tumor immunity by depleting highly suppressive GARP+ regulatory T cells.
Satoh K; Kobayashi Y; Fujimaki K; Hayashi S; Ishida S; Sugiyama D; Sato T; Lim K; Miyamoto M; Kozuma S; Kadokura M; Wakita K; Hata M; Hirahara K; Amano M; Watanabe I; Okamoto A; Tuettenberg A; Jonuleit H; Tanemura A; Maruyama S; Agatsuma T; Wada T; Nishikawa H
Int Immunol; 2021 Jul; 33(8):435-446. PubMed ID: 34235533
[TBL] [Abstract][Full Text] [Related]
19. Cancer immunotherapy with check point inhibitor can cause autoimmune adverse events due to loss of Treg homeostasis.
Kumar P; Saini S; Prabhakar BS
Semin Cancer Biol; 2020 Aug; 64():29-35. PubMed ID: 30716481
[TBL] [Abstract][Full Text] [Related]
20. [Immunosuppressive Environment in Tumors].
Sakai C; Nishikawa H
Gan To Kagaku Ryoho; 2018 Feb; 45(2):222-226. PubMed ID: 29483409
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
